Close Menu

Goldman Sachs

An analyst at the investment firm said that the expanded production of Illumina's HiSeq sequencing platform is expected to result in sequential revenue growth in the first and second quarters of 2011, but revenue growth will likely abate in the third quarter.

A Goldman Sachs analyst said that Myriad's third share repurchase program in less than 12 months "is reflective of slowing organic growth and increasing dependence on financial engineering to drive bottom-line growth."

In addition to initiating coverage of Cepheid, Gen-Probe, Myriad Genetics, and Qiagen, the investment bank also began coverage of Alere and Hologic.

Despite the drop in mass-spec sales, CEO Greg Lucier said "It was a very good quarter for our mass-spec business." Companywide revenues inched up 1 percent to $785M on a pro forma basis.

The change removes "drag from the revenue" but could also fuel speculation that Life Tech is considering divesting the unit. Officials reiterated the firm’s intent to "run the business for success."

News Scan

Premium

MDS, Cenix BioScience, Boehringer Ingelheim, Life Technologies, Molecular Devices

Pages

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.